Spotlight On... Bayer sees new med Kovaltry as just one piece of its hemophilia puzzle; EU green-lights Lilly's Portrazza; Adcock in talks to sell Indian unit; and more...

Earlier this week, Bayer nabbed an EU approval for a new, longer-lasting hemophilia med, Kovaltry. But the company isn't expecting all of the patients on stalwart treatment Kogenate to jump ship for the newcomer--which is why it thinks it's important to offer both. "It's not a market where you see the kind of adoption rates you see in oncology," Hansjoerg Duerr, Bayer Hematology's head of global strategic marketing, told FiercePharmaMarketing in an interview at the J.P. Morgan Healthcare Conference in January. "If people are very satisfied with their current product, it's a step into the unknown." More from FiercePharmaMarketing

@FiercePharma: Bayer sees its new Kovaltry as one arrow in a hemophilia quiver. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: EMA takes aim at another China API producer with manufacturing problems. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Allergan pooh-poohs threat from Shire's prospective dry-eye drug. FiercePharmaMarketing story | Follow @CarlyHFierce

> European regulators have approved Eli Lilly's ($LLY) oncology med Portrazza as a treatment for patients with advanced non-small cell lung cancer. Report

> South Africa's Adcock Ingram says it's in advanced talks over a sale of its Indian sales and marketing unit. Report

> Short-seller Kyle Bass has returned most of the $700 million he raised last year for a high-profile campaign against pharma companies and their patents. Report

> The FDA has accepted Allergan's ($ACT) sNDA for Avycaz as a treatment for complicated intra-abdominal infections and granted the therapy priority review. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: ResMed to offer its customers software-based services thanks to $800M purchase of Brightree. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips unveils wearable, wireless vitals patch that goes from hospital to home. Report | Follow @StacyALawrence

@EmilyWFierce: Two Texas hospitals said that they've developed a rapid test for Zika. More from Reuters | Follow @EmilyWFierce

> Google's Verily, Dexcom aim to launch mini glucose monitor in 2018, with next-gen by 2021. Story

> FDA asks hospitals to stop using Custom Ultrasonics' recalled duodenoscope reprocessor. More

> Israeli PolyPid raises $22M for clinical trials of anti-infective surgical products. Article

Biotech News

@FierceBiotech: Kellogg researchers shine light on new anti-cancer nanoparticle. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: "Woodford's 2 funds have invested a combined £141M in Northwest since 2014." now worth about £40M. More | Follow @JohnCFierce

@DamianFierce: this is Damien Hirst's new restaurant. More | Follow @DamianFierce

> Google backs $75M A round for Stanford's immuno-oncology spinout Forty Seven. Report

> Novo Nordisk's weekly diabetes drug goes 5-for-5 in Phase III. Story

> Israel's PolyPid raises $22M after a couple failed IPO attempts. Article

Biotech Research News

> Kellogg researchers shine light on new anticancer nanoparticle. More

> BU researchers: Key enzyme in a pathway of T-cell leukemia offers a new target. Report

> Juno scientific co-founder Stan Riddell adds another upgrade to CAR-T. Story

> Protein engineering program at Ohio State modulates heart contraction in mice. Item

> Scripps team spotlights a new lupus drug target. Article

Vaccines News

> Philippines' immunization program for Sanofi's Dengvaxia set to start in April. More

> Inovio says Zika vaccine shows promise in mice and shoots for human trial by year-end. Report

> Mitsubishi Tanabe's tobacco-based flu jab to enter late-stage trials this year. Story

> Researchers create first 3-D 'map' of malaria parasite protein. Item

> Brazil funds dengue vaccine PhIII, report says. Article

Pharma Marketing News

> Allergan pooh-poohs threat from Shire's prospective dry-eye drug. Report

> Bayer sees its new Kovaltry as one arrow in a hemophilia quiver. Story

> Will pharma advertisers pay the price for Google's pared-down search pages? More

> WebMD sees rapid online and mobile growth in pharma ads, with more to come. Article

> Side-effects analysis gives Merck's new hep C med Zepatier an edge over older drugs. Item

And Finally... Britain's departure from the European Union would jeopardize the EU's drug regulation system, the European pharmaceutical industry says. More

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.